Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FUSION NHL 001: durvalumab alone and in combination for lymphoma or chronic lymphocytic leukemia
NL-OMON53056Phase 2Recruiting
- Sponsor
- Celgene Corporation
- Start
- Jan 2017
- Modality
- PD-1/PD-L1 Inhibitors → Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label trial of durvalumab in lymphoma, chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) and mature B-cell lymphoma (4 arms), sponsored by Celgene Corporation. Primary endpoints: Non-tolerated dose, maximum tolerated dose, and recommended Phase 2 dose, Treatment-emergent adverse events and 1 more. Started Jan 2017; status: recruiting.
02
Drugs
durvalumab
03
Conditions
lymphomachronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)mature B-cell lymphoma
Beyond the preview
Go deeper on NL-OMON53056.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON53056.